News

38087 readers

2799 users here now

Welcome to the News community!

Rules:

1. Be civil

Attack the argument, not the person. No racism/sexism/bigotry. Good faith argumentation only. This includes accusing another user of being a bot or paid actor. Trolling is uncivil and is grounds for removal and/or a community ban. Do not respond to rule-breaking content; report it and move on.

2. All posts should contain a source (url) that is as reliable and unbiased as possible and must only contain one link.

Obvious biased sources will be removed at the mods’ discretion. Supporting links can be added in comments or posted separately but not to the post body. Sources may be checked for reliability using Wikipedia, MBFC, AdFontes, GroundNews, etc.

3. No bots, spam or self-promotion.

Only approved bots, which follow the guidelines for bots set by the instance, are allowed.

4. Post titles should be the same as the article used as source. Clickbait titles may be removed.

Posts which titles don’t match the source may be removed. If the site changed their headline, we may ask you to update the post title. Clickbait titles use hyperbolic language and do not accurately describe the article content. When necessary, post titles may be edited, clearly marked with [brackets], but may never be used to editorialize or comment on the content.

5. Only recent news is allowed.

Posts must be news from the most recent 30 days.

6. All posts must be news articles.

No opinion pieces, Listicles, editorials, videos, blogs, press releases, or celebrity gossip will be allowed. All posts will be judged on a case-by-case basis. Mods may use discretion to pre-approve videos or press releases from highly credible sources that provide unique, newsworthy content not available or possible in another format.

7. No duplicate posts.

If an article has already been posted, it will be removed. Different articles reporting on the same subject are permitted. If the post that matches your post is very old, we refer you to rule 5.

8. Misinformation is prohibited.

Misinformation / propaganda is strictly prohibited. Any comment or post containing or linking to misinformation will be removed. If you feel that your post has been removed in error, credible sources must be provided.

9. No link shorteners or news aggregators.

All posts must link to original article sources. You may include archival links in the post description. News aggregators such as Yahoo, Google, Hacker News, etc. should be avoided in favor of the original source link. Newswire services such as AP, Reuters, or AFP, are frequently republished and may be shared from other credible sources.

10. Don't copy entire article in your post body

For copyright reasons, you are not allowed to copy an entire article into your post body. This is an instance wide rule, that is strictly enforced in this community.

founded 3 years ago

MODERATORS

JonsJava@lemmy.world

gedaliyah@lemmy.world

little_cow@lemmy.world

430

Trump may be mystery patient in odd case of 79yo getting experimental obesity drug (arstechnica.com)

submitted 1 day ago by ccunning@lemmy.world to c/news@lemmy.world

87 comments fedilink hide all child comments

In an extremely odd case, a single 79-year-old patient was granted early access to Eli Lilly’s powerful, still-experimental obesity drug retatrutide through the Food and Drug Administration’s “compassionate use” program—raising immediate questions if that sole patient is President Donald Trump, according to a report by Stat News.

Lilly’s retatrutide is a highly anticipated next-generation obesity drug that targets GIP and glucagon hormones in addition to GLP-1. It is currently in late-stage trials to treat obesity, diabetes, sleep apnea, and other conditions. Data from a Phase 3 trial that Lilly released in May indicates that patients with obesity (but without diabetes) who took the drug for 80 weeks lost 28 percent of their weight, an amount comparable to bariatric surgery.

Millions of Americans with obesity are eager to get the drug, with options being limited so far to enrolling in a clinical trial or trying to obtain it by dodgy methods.

But according to a barebones public notice and Stat’s sources, a single person has been granted early access through the expanded access, aka “compassionate use” pathway, which is typically used to grant access to patients with a “serious or immediately life-threatening disease or condition” and who are not able to enroll in a clinical trial, often because they are too ill.

The access request was first made in April, when the person was 79 years old (Trump turned 80 on June 14). It was made by a senior clinician at the National Institutes of Health named Ranganath Muniyappa, who requested it on behalf of a patient with refractory obesity, obstructive sleep apnea, and pulmonary hypertension, which is high blood pressure in the lungs. Sources told Stat this patient had spent a year on tirzepatide, a drug that targets the GLP-1 and GIP hormones. But the patient had achieved only moderate weight loss on the drug.

you are viewing a single comment's thread
view the rest of the comments

[–] FreddiesLantern@leminal.space 2 points 7 hours ago

It’s got literal Nazis so that tracks.